Research Article
Portal Hypertensive Polyposis in Advanced Liver Cirrhosis: The Unknown Entity?
Table 1
Demographic data and clinical and laboratory characteristics.
| | | n = 407 | | Age [years], median (range) | 60 (21–88) | | Females/males, n (%) | 127 (31.2%)/280 (68.8%) | | Ethanol (active or past substantial consumption) | 111 (27.3%) | | Hepatitis C | 77 (18.9%) | | Non-alcoholic fatty liver disease | 63 (15.4%) | | Cryptogenic | 40 (9.8%) | | Hepatitis B | 23 (5.7%) | | Primary sclerosing cholangitis | 21 (5.2%) | | Autoimmune hepatitis | 15 (3.7%) | | Hemochromatosis | 9 (2.2%) | | Wilson’s disease | 7 (1.7%) | | Primary biliary cirrhosis | 5 (1.2%) | | Miscellaneous | 36 (8.8%) | | Splenomegaly | 328 (82.8%) | | Ascites | 228 (56.4%) | | Encephalopathy | 118 (29.0%) | | I–II | 103 (25.3% of all patients) | | III–IV | 15 (3.7% of all patients) | | Thrombocyte count | 101 (18–630) thousand/µl | | International normalized ratio | 1.3 (0.86–4.80) | | Creatinine | 1 (0.10–16.60) mg/dL | | Albumin | 3.3 (0.20–4.80) g/dL | | Bilirubin | 3.9 (0.2–40.1) mg/dL | | Child-Pugh score | | | ≤ 6 | 142 (34.9%) | | > 6 | 265 (65.1%) | | Child-Pugh class | | | A | 142 (34.9%) | | B | 158 (38.8%) | | C | 107 (26.3%) | | Model for End Stage Liver Disease score, mean ± SD/ median (range) | 15.2 ± 7.3/ 13 (6–40) | | Portal vein thrombosis | 35 (8.6%) | | Hepatocellular carcinoma | 78 (19.2%) | | Beta-blocker | 299 (73.5%) | | Proton-pump inhibitor | 378 (92.9%) |
|
|
